Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Stock Rating Reaffirmed by Aegis

Cornelia Mascio
Luglio 8, 2017

On average, equities research analysts expect that Alder BioPharmaceuticals, Inc. will post ($6.33) earnings per share for the current fiscal year. Candriam Luxembourg S.C.A. boosted its stake in shares of Alder BioPharmaceuticals by 172.5% in the first quarter. Jefferies Group LLC reaffirmed a buy rating and issued a $43.00 target price on shares of Alder BioPharmaceuticals in a research report on Thursday, March 30th. Vanguard Group Inc. now owns 3,438,702 shares of the biopharmaceutical company's stock worth $71,524,000 after buying an additional 194,185 shares during the period. Redmile Group LLC increased its stake in Alder BioPharmaceuticals by 107.5% in the first quarter. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by $1.04. The stock notched a 12-month high of $32.78 while $47.00 target is by far the most aggressive out of analysts who are now evaluating the company, $14.22 higher than the next highest 52-week price estimate. Wells Fargo & Company reiterated an "outperform" rating and set a $51.00 price objective on shares of Alder BioPharmaceuticals in a research note on Wednesday, June 28th.

Shares of Alder BioPharmaceuticals, Inc. About 2.11M shares traded or 27.11% up from the average. State Board of Administration of Florida Retirement System now owns 21,965 shares of the biopharmaceutical company's stock valued at $457,000 after buying an additional 160 shares during the last quarter. Arrowpoint Asset Management LLC now owns 21,000 shares of the biopharmaceutical company's stock valued at $437,000 after buying an additional 468 shares during the last quarter. During the same quarter in the previous year, the firm posted ($0.76) earnings per share. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & worldwide copyright laws. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company's stock valued at $1,598,000 after buying an additional 1,171 shares during the last quarter. Piper Jaffray Companies reiterated an "overweight" rating and set a $47.00 price objective on shares of Alder BioPharmaceuticals in a research note on Wednesday, June 28th. The original version of this news story can be accessed at https://sportsperspectives.com/2017/07/06/alder-biopharmaceuticals-inc-aldr-raised-to-sell-at-valuengine-updated.html. Aegis reiterated a "buy" rating and issued a $41.00 target price on shares of Alder BioPharmaceuticals in a report on Monday, April 10th. Credit Suisse Group cut shares of Alder BioPharmaceuticals from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $30.00 to $17.00 in a research report on Wednesday, June 28th.

Shares of Alder BioPharmaceuticals (NASDAQ ALDR) traded up 3.93% during midday trading on Wednesday, hitting $11.90. 138,641 shares of the stock traded hands. Needham analysts stated on 16/05/2017 that they launched coverage on this stock with Buy rating. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company's stock valued at $107,473,000 after buying an additional 230,044 shares in the last quarter. The firm's 50 day moving average is $17.91 and its 200 day moving average is $20.80. The company has an average rating of "Buy" and an average price target of $38.18.

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The stock's market cap is $602.40 million. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE